{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:56:56Z","timestamp":1790773016227,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Introduction: Over the last decade, the regulation of cannabinoids and cannabis-based\nmedicinal products has undergone significant transformation, determined by growing evidence of\ntheir therapeutic value and increasing concerns about safety, misuse, and product diversion. The objective\nof this review was to examine current regulatory frameworks across major jurisdictions from\na public health policy perspective, highlighting how different approaches seek to balance patient\naccess with health protection.\nMethods: This review followed a targeted literature search in scientific databased (PubMed and\nGoogle Scholar) to identify publications in English language addressing the evolution of medical\ncannabis and cannabinoid policies, with particular emphasis on the regulatory frameworks in various\ncountries. The identified literature was qualitatively analyzed to evaluate the relationship between\ninternational policy developments and the evolution of national medical cannabis regulations\nand research activities.\nResults: This review identified three primary regulatory models: traditional pharmaceutical approval\npathways that require robust clinical evidence; alternative access mechanisms, e.g., compassionate-\nuse and special access programs; and regulatory systems which have varying levels of regulatory\noversight, quality control, and patient protections, especially the vulnerable population.\nDiscussion: While there has been an increasing global acceptance of cannabinoid-based therapies,\nconsiderable differences in regulatory requirements remain across countries. Such a fragmentation\ncreates barriers to clinical research on cannabinoids and cannabis products, obscures patient access,\nand limits effective public health surveillance. Additionally, challenges related to product quality,\nstandardization, labeling accuracy, and pharmacovigilance are particularly obvious for botanical\ncannabis products, where regulatory expectations often differ from those applied to conventional\nmedicines. At the same time, innovative regulatory developments are emerging.\nConclusion: The review highlights that a greater international regulatory harmonization, stronger\nquality assurance frameworks, and evidence-based monitoring systems are required for cannabinoids\nand cannabis products. These aspects are crucial for protecting public health, supporting\nscientific research, and enabling the responsible integration of cannabinoid-based therapies into\nmodern healthcare systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0127724328501726260907075438","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:56:58Z","timestamp":1790769418000},"source":"Crossref","is-referenced-by-count":0,"title":["Global Regulatory Frameworks for Cannabinoids and Cannabis-Based Medicinal Products: A Comprehensive Review of Contemporary Approaches and Challenges"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0269-8451","authenticated-orcid":true,"given":"Shalini","family":"Dwivedi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Amity University, Amity Education Valley Gurugram (Manesar), Haryana122 413, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5836-1798","authenticated-orcid":true,"given":"Jeanine Giarolla","family":"Vargas","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-3693","authenticated-orcid":true,"given":"Samridhi","family":"Lal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Amity University, Amity Education Valley Gurugram (Manesar), Haryana122 413, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328501726260907075438","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258747\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328501726260907075438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:57:31Z","timestamp":1790769451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258747\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328501726260907075438","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}